Search Results
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
highly malignant tumor of the central nervous system (CNS), most commonly affecting young children. It is characterized by loss of the SMARCB1 (INI1) gene, or, less frequently, SMARCA4, resulting in disruption of the SWI/SNF chromatin-remodeling complex and widespread epigenetic dysregulation. Clinically,
More news about: DelveInsight Business Research, LLP
Oct 30, 2025, 16:05 ET Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
to the Alliance for Genomic Discovery (AGD), broadening the consortium's diverse clinical genomic dataset and utilizing it to inform development of 'gene silencing' medicines Introduced Illumina® Protein Prep, driving deeper proteomic insights to enhance drug discovery and development,
More news about: Illumina, Inc.
Oct 30, 2025, 10:35 ET Cardiovascular, Renal & Metabolic (CRM) Diseases Market to Reach USD 451.87 Billion by 2033, Driven by Rising Burden of Chronic Conditions | DataM Intelligence
consulting, and competitive intelligence solutions. The firm's oncology market coverage spans hematologic malignancies, solid tumors, and cell & gene therapies, providing deep-dive data on clinical pipelines, regulatory landscapes, pricing, and market access strategies.
More news about: DataM Intelligence 4 Market Research LLP
Oct 30, 2025, 10:30 ET Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the short term and $32.3 billion by 2034 Globally, at 9.6% CAGR: Allied Market Research
the respiratory and digestive systems. CF is caused by mutations in the CFTR gene, leading to thick mucus buildup in various organs. Over recent years, the market has witnessed significant growth due to advancements in gene-targeted therapies, including CFTR modulators such as ivacaftor, lumacaftor,
More news about: Allied Market Research
Oct 30, 2025, 10:01 ET Livestock Genomics Testing Market to Reach $3,691.4 million, Globally, by 2034 at 9.3% CAGR: Allied Market Research
Market by Test Type (Genotyping Services, Whole Genome Sequencing (WGS), Trait Testing, Genomic Selection (gEBV), Embryo Testing, Disease Gene Screening, and Others) and Application (Selective Breeding, Productivity Enhancement, Food Safety, Disease Resistance, and Others): Global Opportunity
More news about: Allied Market Research
Oct 30, 2025, 10:00 ET Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research
oncoReveal® Essential MPN, a rapid 3-gene NGS panel designed to quickly streamline the evaluation of myeloproliferative neoplasms (MPN) through the interrogation of JAK2, CALR and MPL, is the
More news about: Pillar Biosciences, Inc.
Oct 30, 2025, 08:52 ET Global Location Strategies Report: $350 Billion U.S. Pharmaceutical Manufacturing Investment Boom Challenged by Labor Shortages, Tariffs and Policy Shifts
U.S. remains the world's largest biologics market (48% of global revenues). Therapeutic biologics, such as monoclonal antibodies, recombinant proteins, gene and cell therapies, and therapeutic vaccines, represent the fastest-growing segment of global medicine, transforming treatment for cancer, autoimmune
More news about: Global Location Strategies
Oct 30, 2025, 08:30 ET Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain
ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn., Oct.
More news about: Cryoport, Inc.
Oct 30, 2025, 08:05 ET Avantor® Unveils Next-Generation Sterile Sampling Platform and PUPSIT Assemblies
and conical tubes. EVSS (Exact Volume Sampling System): Provides closed, precise small-volume sampling ideal for cell and gene therapy applications where accuracy and material conservation are essential. OmniTop: Offers weld-on or aseptic connection
More news about: Avantor and Financial News
Oct 30, 2025, 07:05 ET REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
80% full capsids, the highest in Duchenne gene therapy. REGENXBIO can produce 2,500 doses of RGX-202 per year. About RGX-202 RGX-202 is a potential best-in-class investigational gene therapy designed for improved function
More news about: REGENXBIO Inc.
Oct 30, 2025, 07:00 ET Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
Gene Therapy Insmed completed dosing of the first cohort in the Phase 1 ASCEND clinical study of INS1201, an intrathecally-delivered gene therapy for patients with Duchenne
More news about: Insmed Incorporated
Oct 30, 2025, 04:08 ET 중국관, 2025 오사카 박람회에서 금상 수상! 유니루민, 종합 멀티미디어 솔루션 전시
관람객은 몰입형 공간에서 마치 시간과 자연을 오가는 듯한 체험을 할 수 있었다. 또한 유니루민은 수묵화, 비단, 산수화 같은 동양적 요소를 디지털 언어로 승화시킨 획기적인 '문화유산 디지털 유전자은행(Cultural Digital Gene Bank)'도 구현했다. 이러한 요소들은 다른 전시물에도 유연하게 응용되었다. '적응형 주변광 조절 시스템(Adaptive Ambient Light Adjustment System)'과 짝을 이룬 LED 화면 기반의 상호 작용형 전시 장치가 건축 공간과 거의 완벽하게
More news about: Unilumin Group., Ltd.
Oct 30, 2025, 02:18 ET Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
to request Priority Review. Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, the latter reported as a subsequent event, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of gene therapy, which is very exciting."
More news about: Hansa Biopharma AB
Oct 30, 2025, 02:16 ET Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
to request Priority Review. Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, the latter reported as a subsequent event, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of gene therapy, which is very exciting."
More news about: Hansa Biopharma AB
Oct 30, 2025, 01:21 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:15 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information
More news about: Piramal Pharma Solutions
Oct 29, 2025, 23:38 ET China Pavilion at Osaka Expo 2025 wins the Gold Award! Unilumin provides a comprehensive multimedia solution
they were traveling between time and nature in an immersive space. Unilumin's team also innovatively created a "Cultural Digital Gene Bank", transforming Oriental elements such as ink wash, silk, and landscapes into digital language. These elements were flexibly applied in other exhibition
More news about: Unilumin Group., Ltd.
Oct 29, 2025, 23:06 ET China Pavilion at Osaka Expo 2025 wins the Gold Award! Unilumin provides a comprehensive multimedia solution
they were traveling between time and nature in an immersive space. Unilumin's team also innovatively created a "Cultural Digital Gene Bank", transforming Oriental elements such as ink wash, silk, and landscapes into digital language. These elements were flexibly applied in other exhibition
More news about: Unilumin Group., Ltd.
Oct 29, 2025, 18:34 ET CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety profile. Successful genetic delivery
More news about: CREATE Medicines, Inc.
Oct 29, 2025, 15:08 ET Silver Wound Dressing Market to Reach USD 2,129.8 million by 2032, Growing At An 4.19% CAGR - Credence Research
In October 2024, Mölnlycke Health Care partnered with Transdiagen to advance research using TDG's wound gene signatures, aiming to enhance innovation and understanding in chronic wound care solutions. In September 2024, 3M's Solventum
More news about: Credence Research Inc.
Oct 29, 2025, 14:00 ET Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Oct 29, 2025, 13:57 ET Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hansa Biopharma AB
Oct 29, 2025, 09:00 ET ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
delighted that Q-FMB® technology generates significant cost and time savings while advancing the safety of gene editing." In addition to its focus on gene editing, ICHORtec plans to launch diagnostic testing for Methicillin-Resistant Staphylococcus aureus (MRSA) and Multidrug-Resistant Tuberculosis
More news about: ICHORtec GmbH
Oct 29, 2025, 09:00 ET ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology
delighted that Q-FMB® technology generates significant cost and time savings while advancing the safety of gene editing." In addition to its focus on gene editing, ICHORtec plans to launch diagnostic testing for Methicillin-Resistant Staphylococcus aureus (MRSA) and Multidrug-Resistant Tuberculosis
More news about: ICHORtec GmbH
Oct 29, 2025, 08:34 ET GeneVentiv Therapeutics Announces Positive FDA INTERACT Feedback Supporting Advancement of GENV-HEM Gene Therapy for Hemophilia A with or without Inhibitors
held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting with the U.S. Food and Drug Administration (FDA) for the Company's lead program, GENV-HEM, a novel gene therapy for Hemophilia A with or without inhibitors
More news about: GeneVentiv Therapeutics